ArticleCureus2026
Efficacy of Intra-articular Platelet-Rich Fibrin Injection for Periarthritis of the Shoulder: A Pilot Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Outcome Analysis of Leukocyte-Rich Platelet-rich Plasma, Leukocyte-Poor Platelet-rich Plasma, Injectable Platelet-rich Fibrin and Corticosteroid Injections in Periarthritis of the Shoulder: A Double-Blinded, Four-Arm Randomized Controlled Trial.Journal of orthopaedic case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Periarthritis of the shoulder (adhesive capsulitis) is a common and disabling condition characterized by pain and progressive restriction of shoulder motion. Conventional treatment modalities often provide inconsistent long-term outcomes. Platelet-rich fibrin (PRF) is an autologous biological product with regenerative and anti-inflammatory properties, though evidence for its intra-articular use in periarthritis remains limited. Objective To evaluate the clinical outcomes and safety of a single intra-articular injectable PRF (i-PRF) injection in patients with periarthritis of the shoulder. Methods This prospective single-arm interventional pilot study included 30 patients with periarthritis of the shoulder of less than six months' duration. All patients received a landmark-guided intra-articular i-PRF injection (approximately 3-4 mL) prepared using low-speed centrifugation (700 RPM, 60g at radius 110 mm, 3 minutes). Outcomes were assessed using the visual analog scale (VAS), Shoulder Pain and Disability Index (SPADI), and shortened Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) at baseline, immediate post-procedure, and at 2, 4, 8, and 12 weeks. Statistical analysis was performed using repeated measures analysis of variance (ANOVA). Results All patients completed the 12-week follow-up. Mean VAS scores improved significantly from 7.8 ± 1.2 at baseline to 1.5 ± 0.7 at 12 weeks (81% improvement, Cohen's
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.